Entering text into the input field will update the search result below

BioSci Research On Myovant Sciences (Part I): Is This A Big Winner In The Making?


  • Myovant is innovating a stellar molecule (Relugolix) for the treatment of pain and heavy bleeding associated with endometriosis and uterine fibroids, respectively.
  • Relugolix is also being investigated as a potential treatment of advanced prostate cancer.
  • The three aforesaid franchises have a stellar chance of delivering positive outcomes in 2019 (and to gain regulatory approvals).

Through the entire twentieth century, with a single exception, every time major war has broken out anywhere in the world or whenever American forces have become involved in any fighting, whatever, the American stock market has always plunged sharply downward. At the condition of actual fighting most stocks were selling at levels vastly higher than prevailed before there was any thought of war at all. - The Father of Growth Investing (Philip Fisher)

Myovant Sciences (NASDAQ:NYSE:MYOV) is an unpopular company on Wall Street. Most investors have yet to hear this name. In the Integrated BioSci Rounds Report, we came across this potential big winner through our tracking of insider transactions. Notably, the company is brewing an enriched pipeline of advanced-stage molecules, seeking to fulfill the needs of women as well as men’s health. And, there is the substantial unlocked value of this pipeline which positioned the firm to become a multifold winner within next few years.

Despite its low profile status, some whale investors have been purchasing shares aggressively to send the stock on an uptrend. As follows, the share price traded north by $9.96 at $21.20 for over 88% profits in the past year. In this report, we’ll elucidate the fundamentals as well as the substantial pipeline’s prospects for investors to decide whether they should invest in this bioscience.

Figure 1: Myovant Sciences stock chart. (Source: StockCharts)

Fundamental Analysis

Based in Brisbane, CA, Myovant is focused on the therapeutics innovation that serves women’s health, endocrine diseases in areas of high unmet needs, and prostate cancer. The company is powering an interesting pipeline of medicine (as shown in figure 2). At the heart of the pipeline is Relugolix - an oral, once-daily, GnRH receptor blocker that is currently being assessed in the Phase 3 (LIBERTY1/2, SPIRIT1/2, and

Author’s Notes: We’re honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (“IBI”) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 398%, 86%, 151%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Subscribe to our marketplace now to lock in the current price and save money for the future.

This article was written by

BioSci Capital Partners profile picture
The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I like to inform our readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.